Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Idiopathic CD4+ lymphocytopenia (ICL) is a rare syndrome that is marked by a CD4+ count that is less than 300 cells/mm3 without human immunodeficiency virus infection.1 Its course differs from that of AIDS in that although patients with this disorder may develop opportunistic infections, the majority of them remain stable. No transmissible agent has been implicated in the pathogenesis of ICL. The ocular manifestations of ICL have only rarely been described,2 and there are no reports of ICL in ophthalmology literature. We report the case of a patient with ICL and Sjogren syndrome.
A 52-year-old woman was referred to the ophthalmology department because of a several-year history of burning and stinging in both eyes. Her medical history was significant for ICL, with 5 CD4+ counts during 6 years ranging from 93 to 253, despite 3 negative human immunodeficiency virus test results. Additionally, assays for Epstein-Barr virus, cytomegalovirus, and human herpesviruses 6 and 8 were all negative. At the time, her visual acuity was 20/20 OD and 20/25 OS. The patient had marked superficial punctate keratitis and abundant mucus production in both eyes, and as a result, she began a course of applying artificial tears to both eyes every 2 hours with only minimal relief.
During the ensuing months, a bandage contact lens was placed over the patient’s left eye, but it failed to relieve her symptoms. Schirmer testing with topical anesthesia showed 6 mm of tearing in the right eye and 5.5 mm in the left. Subsequent bilateral inferior punctual plug placement provided some relief, but her symptoms and superficial punctate keratitis persisted. In addition to the aggressive use of artificial tears, other modalities (corticosteroid eye drops and systemic doxycycline administration) were employed, but the patient’s condition did not improve.
A diagnosis of Sjogren syndrome was confirmed after testing showed a Sjogren syndrome antigen antibody level of 13.1 (range, 0-4.9 U/mL). The patient then began a course of cevimeline hydrochloride (30 mg by mouth 3 times a day), and her symptoms improved considerably. Furthermore, her superficial punctate keratitis diminished appreciably. She remains stable and comfortable on this regimen with the use of artificial tears 4 times per day.
Idiopathic CD4+ lymphocytopenia is a rare disorder of CD4+ lymphocytopenia without human immunodeficiency virus infection. The ophthalmic sequelae of this syndrome have not yet been elucidated. In this report, we describe the characteristics and clinical courses of a patient with ICL and Sjogren syndrome.
The underlying pathophysiology of ICL results from apoptosis of CD4+ cells,3 with subsequent limitations on the repertoire of the T-cell population.4 Autoimmune processes such as Sjogren syndrome may result from restriction of T-cell diversity, which may lead to a subsequent decrease in immune surveillance. This scenario would allow autoantibodies that may otherwise be cleared from systemic circulation to flourish. Kirtava et al2 found an increased prevalence of ICL among patients with Sjogren syndrome.
In summary, both ophthalmologists and internists should be aware of the connection between Sjogren syndrome and patients with ICL. Further evaluation is necessary to determine other ocular manifestations of ICL.
Correspondence: Dr Chu, Doctor’s Office Center, Sixth Floor, 90 Bergen St, Newark, NJ 07103 (chuda@umdnj.edu).
Financial Disclosure: None.
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Comments are moderated and will appear on the site at the discretion of the Archives of Ophthalmology editors. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 4
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Register Now
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.